Regulatory Norgine gets first EU approval for WHIM syndrome therapy PharmaphorumPatients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.Rare DiseaseRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaphorum Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine’s Xolremdi. Rare Disease Read full story Post navigation Previous: Regeneron Q1 2026 net income falls 10% to $727mNext: GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026